By Bilioine Young
Progenza, a stem cell product made by Regeneus LTD, will be the subject of a clinical trial designed to determine the safety, tolerability and preliminary efficacy of intra-articular Progenza in adults with symptomatic knee osteoarthritis.
An independent Human Research Ethics Committee registered with the Australian Government’s National Health and Medical Research Council approved of the trial. It will also be registered on the Australian New Zealand Clinical Trials Registry and notified to the Therapeutic Goods Administration through the Clinical Trials Notification Scheme.
Progenza is produced from adipose tissue from a healthy donor who has been extensively screened. Company officials claim that adipose tissue is readily available from donors in large quantities and has significantly higher mesenchymal stem cells (MSCs) per gram of tissue than other tissue sources such as bone marrow or cord tissue.
